The pathogenesis of ovarian hyperstimulation syndrome: A continuing enigma

Journal of Assisted Reproduction and Genetics

Volumn 15, Issue 4, 1998, Pages 202-209

  Simon, Alexander ^a   Revel, Ariel ^a   Hurwitz, Arye ^a   Laufer, Neri ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Induction of ovulation; Ovarian hyperstimulation syndrome

Indexed keywords

ARTICLE; HUMAN; LUTEINIZING HORMONE RELEASE; OVARY HYPERSTIMULATION; OVULATION; OVULATION INDUCTION; PATHOGENESIS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

CAPILLARY PERMEABILITY; CLOMIPHENE; CYTOKINES; ENDOTHELIAL GROWTH FACTORS; FEMALE; HORMONES; HUMANS; LYMPHOKINES; NITRIC OXIDE; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION; PROSTAGLANDINS; RENIN-ANGIOTENSIN SYSTEM; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

FALLOPIA;

EID: 0031949388     PISSN: 10580468     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023052419627     Document Type: Article

References (72)

1. Schenker JG, Weinstein D: Ovarian hyperstimulation syndrome: A current survey. Fertil Steril 1978;30:255-268
2. Schenker JG: Prevention and treatment of ovarian hyperstimulation. Hum Reprod 1993;8:653-659
3. Haning RV Jr, Austin CW, Carlson IH, Kuzma DL, Shapiro SS, Zweibel WJ: Plasma estradiol is superior to ultrasound and urinary estradiol glucuronide as a predictor of ovarian hyperstimulation during induction of ovulation with menotropins. Fertil Steril 1983;40:31-36
4. Rabau E, David A, Serr DM, Mashiach S, Lunenfeld B: Human menopausal gonadotropins for anovulation and sterility: Results of 7 years of treatment. Am J Obstet Gynecol 1967; 98:92-98
5. Tulandi T, Mclnnes RA, Arronet GH: Ovarian hyperstimulation syndrome following ovulation induction with human menopausal gonadotropin. Int J Fertil 1984;29:113-117
6. Golan A, Ron-El R, Herman A, Weinraub Z, Soffer Y, Caspi E: Ovarian hyperstimulation syndrome following D-Trp-6 luteinizing hormone-releasing hormone microcapsules and menotropin for in vitro fertilization. Fertil Steril 1988; 50:912-916
7. Borenstein R, Elhalal U, Lunenfeld B, Schwartz ZS: Severe ovarian hyperstimulation syndrome: A re-evaluated therapeutic approach. Fertil Steril 1989;51:791-795
8. Herman A, Ron-El R, Golan A, Raziel A, Soffer Y, Caspi E: Pregnancy rate and ovarian hyperstimulation after luteal human chorionic gonadotropin in in vitro fertilization stimulated with gonadotropin-releasing hormone analog and menotropins. Fertil Steril 1990;53:92-96
9. Forman RG, Frydman R, Egan D, Ross C, Barlow DH: Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: A European series and a proposal for prevention. Fertil Steril 1990; 53:502-509
10. Smitz J, Camus M, Devroey P, Erard P, Wisanto A, Van Steirteghem AC: Incidence of severe ovarian hyperstimulation syndrome after GnRH agonist/HMG superovulation for in-vitro fertilization. Hum Reprod 1990;5:933-937
11. Rizk B, Tan SL, Morcos S, Riddle A, Brinsden P, Mason BA, et al.: Heterotopic pregnancies after in vitro fertilization and embryo transfer. Am J Obstet Gynecol 1991;164:161-164
12. MacDougall MJ, Tan SL, Jacobs HS: In-vitro fertilization and the ovarian hyperstimulation syndrome. Hum Reprod 1992; 7:597-600
13. Southan AL, Janovsky NA: Massive ovarian hyperstimulation with clomiphene citrate. JAMA 1962;200:443
14. Scommegna A, Lash SR: Ovarian hyperstimulation, massive ascites, and singleton pregnancy after clomiphene. JAMA 1969;207:753-755
15. Pappas GD, Blanchette EJ: Transport of colloidal particles fron small blood vessels correlated with cyclic changes in permeability. Invest Ophthalmol 1965;4:1026-1036
16. Pride SM, James C, Ho Yuen B: The ovarian hyperstimulation syndrome. Semin Reprod Endocrinol 1990;8:247-260
17. Pellicer A, Miro F, Sampaio M, Gomez E, Bonilla-Musoles FM: In vitro fertilization as a diagnostic and therapeutic tool in a patient with partial 17,20-desmolase deficiency. Fertil Steril 1990;55:970-975
18. Meirow D, Schenker JG, Rosler A: Ovarian hyperstimulation syndrome with low estradiol in non classic 17alpha-hydroxylase, 17,20-lyase deficiency: What is the role of oestrogens? Hum Reprod 1996;11:2119-2121
19. Knox GE: Antihistamine blockage of the ovarian hyperstimulation syndrome. Am J Obstet Gynecol 1974;118:992-999
20. Gregely RZ, Paldi E, Erlik Y, Makler A: Treatment of ovarian hyperstimulation syndrome by antihistamine. Obstet Gynecol 1976;47:83-85
21. Pride SM, Ho Yuen B, Moon YS: Clinical, endocrinologic, and intraovarian prostaglandin F responses tp H-l receptor blockade in the ovarian hyperstimulation syndrome: studies in the rabbit model. Am J Obstet Gynecol 1984;148:670-674
22. Erlik Y, Naot Y, Friedman M, Ben-David E, Paldi E: Histamine levels in ovarian hyperstimulation syndrome. Obstet Gynecol 1979;53:580-582
23. Katz Z, Lancet M, Borenstein R, Chemke J: Absence of teratogenicity of indomethacin in ovarian hyperstimulation syndrome. Int J Fertil 1984;29:186-188
24. Yuen BH, McComb P, Sy L, Lewis J, Cannon W: Plasma prolactin, human chorionic gonadotropin, estradiol, testosterone, and progesterone in ovarian hyperstimulation syndrome. Am J Obstet Gynecol 1979;133:316-320
25. Raabe MA, McCoshen JA: Epithelial regulation of prolactin effect on amniotic permeability. Am J Obstet Gynecol 1986;154:130-134
26. Niederer W, Richardson BP, Donatsch P: Hormonal control of aqueous humour production. Exp Eye Res 1975;20:329-340
27. Leung P, Ho Yuen B, Moon YS: Effect of prolactin in an experimental model of the ovarian hyperstimulation syndrome. Am J Obstet Gynecol 1983;145:847-849
28. Navot D, Margalioth EJ, Laufer N, Birkenfeld A, Relou A, Rosier A, et al.: Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril 1987;48:57-61
29. Itskovitz J, Sealey JE: Ovarian prorenin renin-angiotensin system. Obstet Gynecol Surv 1987;42:545-551
30. Ezra Y, Simon A, Yaron A, Laufer N, Navot D: Angiotensin-I-converting enzyme and its correlation with human follicular fluid steroids. Eur J Obstet Gynecol Reprod Biol 1992; 44:71-75
31. Morris RS, Paulson RJ: The ovarian renin angiotensin system: Recent advances and their relationship to assisted reproductive technologies. Assist Reprod Rev 1993;3:2-6
32. Delbaere A, Bergmann PJM, Gervy-Decoster C, Staroukine M, Englert Y: Angiotensin II immunoreactivity is elevated in ascites during severe ovarian hyperstimulation syndrome: Implication for pathophysiology and clinical management. Fertil Steril 1994;62:731-737
33. Fernadez LA, Twickler J, Mead A: Neovascularization produced by angiotensin II. J Lab Clin Med 1985;105:141-145
34. Paulson RJ, Do YS, Hsueh WA, Eggena P, Lobo RA: Ovarian renin production in vitro and in vivo: Characterization and clinical correlation. Fertil Steril 1989;51:634-638
35. Alexander RW, Gimborne MA Jr: Stimulation of prostaglandin E synthesis in cultured human umbilical vein smooth muscle cells. Proc Natl Acad Sci USA 1976;73:1617-1620
36. Robertson AL, Khairallah PA: Effects of angiotensin II and some analogues on vascular permeability in the rabbit. Circ Res 1972;31:923-931
37. Morris RS, Wong IL, Paulson RJ: Angiotensin-converting enzyme-inhibition of the gonadotropin-stimulated rabbitEffect on estradiol production. J Assist Reprod Genet 1995;12:326-329
38. Morris RS, Wong IL, Kirkman E, et al.: Inhibition of ovarianderived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome. Hum Reprod 1995; 10:1355-1358
39. Sifton DW (ed): Physician Desk Reference. Montvale, NJ, Medical Economics, 1994, pp 1556-1557
40. Briggs GG, Freeman RK, Yaffe SJ (eds): Drugs in Pregnancy and Lactation, 3rd ed. Baltimore, Williams and Wilkins, 1990, pp 83-87, 232-235
41. Pellicer A, Palumbo A, DeCherney AH, Naftolin F: Blockade of ovulation by an angiotensin antagonist. Science 1988; 240:1660-1661
42. Adashi EY: The potential relevance of cytokines to ovarian physiology: The emerging role of resident ovarian cells of the white blood cell series. Endocr Rev 1990;11:454-464
43. Dinarello CA: Interleukin-1 and its related cytokines. Adv Immunol 1989;44:153-205
44. Loukides JA, Loy RA, Edwards R, Honig J, VisintinI, Polan ML: Human follicular fluids contain tissue macrophages. J Clin Endocrinol Metab 1990;71:1363-1367
45. Arid A, Oral E, Bukulmez O, Buradagunta S, Engin O, Olive DL: Interleukin-8 expression and modulation in human preovulatory follicles and ovarian cells. Endocrinology 1996; 137:3762-3769
46. Sirotkin AV, Luck MR: Potential leukocyte attractants in the bovine periovulatory ovary. Reprod Nutr Dev 1995;35:675-683
47. Cavender JL, Murdoch WJ: Morphological studies of the microcirculatory system of periovulatory ovine follicles. Biol Reprod 1988;39:989-997
48. Dinarello CA: Interleukin-1 and interleukin-1 antagonism. Blood 1991;77:1627-1652
49. Friedlander MA, Loret de Mola JR, Goldfarb JM: Elevated levels of interleukin-6 in ascites and serum from women with ovarian hyperstimulation syndrome. Fertil Steril 1993; 60:826-833
50. Hurwitz A, Loukides J, Ricciarelli E, Botero L, Katz E, McAllister JM, Garcia JE, Rohan R, Adashi EY, Hernandez ER: Human intraovarian interleukin-1 (IL-1) system: highly compartmentalized and hormonally dependent regulation of the genes encoding IL-1, its receptor, and its receptor antagonist. J Clin Invest 1992;89:1746-1754
51. Revel A, Barak V, Lavy Y, Anteby E, Amit A, Finci-Yeheskel Z, et al.: Characterization of intraperitoneal cytokines and nitrites in women with severe ovarian hyperstimulation syndrome. Fertil Steril 1996;66:66-71
52. Abramov Y, Schenker JG, Lewin A, Friedler S, Nisman B, Barak V: Plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndrome. Hum Reprod 1996;11:1381-1386
53. Orvieto R, Ben-Rafael Z: The immune system in severe ovarian hyperstimulation syndrome. Isr J Med Sei 1996;32:1180-1182
54. Motro B, Itin A, Sachs I, Keshet E: Pattern of IL-6 gene expression in vivo suggests a role for this cytokine in angiogenesis. J Cell Biol 1990;87:3092-3096
55. Veale D, Yanni G, Bresnihan B, FitzGerald O: Production of angiotensin converting enzyme by rheumatoid synovial membrane. Ann Rheum Dis 1992;51:476-480
56. Watson JM, Sensintaffar JL, Berek JS, Martinez-Maza O: Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res 1990; 50:6959-6965
57. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ: Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996;271:736-741
58. Loret de Mola JR, Flores JP, Baumgardner GP, Goldfarb JM, Gindlesperger V, Friedlander MA: Elevated interleukin-6 levels in the ovarian hyperstimulation syndrome: Ovarian immunohistochemical localization of interleukin-6 signal. Obstet Gynecol 1996;87:581-587
59. Kishimoto T: The biology of IL-6. Blood 1989;74:1-10
60. Terranova PF, Sancho-Teilo M, Hunter VG: TNF and ovarian function. In The Ovary, EY Adashi, CK Leung, (eds). New York, Raven Press, 1993, pp 395-411
61. Loret de Mola JR, Baumgardner GP, Goldfarb JM, Friedlander MA: Ovarian hyperstimulation syndrome: Pre-ovulatory serum concentrations of interleukin-6, interleukin-1 receptor antagonist and tumour necrosis factor-alpha cannot predict its occurrence. Hum Reprod 1996;11:1377-1380
62. Robertson D, Selleck K, Suikkari AM, Hurley V, Moohan J, Healy D: Urinary vascular endothelial growth factor concentrations in women undergoing gonadotrophin treatment. Hum Reprod 1995;10:2478-2482
63. Neulen J, Yan Z, Raczek S, Weindel K, Keck C, Weich HA, etal.: Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: Importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 1995;80:1967-1971
64. McClure N, Healy DI, Rogers PA, Sullivan J, Beaton L, Haning Jr RV, et al.: Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994;344:235-236
65. Krasnow JS, Berga SL, Guzick DS, Zeleznik AJ, Yeo KT: Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: A preliminary report. Fertil Steril 1996;65:552-555
66. Abramov Y, Brak V, Nisman B, Schenker JG: Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil Steril 1997;67:261-265
67. Van Voorhis BJ, Dunn MS, Snyder GD, Weiner CP: Nitric oxide: An autocrine regulator of human granulosa-luteal cell steroidogenesis. Endocrinology 1994;135:1799-1806
68. Shukovski L, Tsafriri A: The inVolvement of nitric oxide in the ovulatory process in the rat. Endocrinology 1994;135: 2287-2290
69. Ben Shlomo I, Kokia E, Jackson MJ, Adashi EY, Payne DW: Interleukin-1 beta stimulates nitrite production in the rat ovary: Evidence for heterologous cell-cell interaction and for insulinmediated regulation of the inducible isoform of nitric oxide synthase. Biol Reprod 1994;51:310-318
70. Fillep JG, Foldes-Filep E, Sirois P: Nitric oxide modulates vascular permeability in the rat coronary circulation. Br J Pharmacol 1993;108:323-326
71. Kubes P, Granger DN: Nitric oxide modulates microvascular permeability. Am J Physiol 1992;262:611-615
72. McCall TB, Boughton-Smith NK, Palmer RM, Whittle BJ, Moncada S: Synthesis of nitric oxide from L-arginine by neutrophils. Biochem J 1989;261:293-296